Grant✓ Small businesses may apply
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
National Institutes of Health
Program funding
$5,500,000
- Opportunity #
- RFA-MH-27-135
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.242, 93.279
- Status
- posted
- Posted
- Apr 29, 2026
- Closes
- Oct 11, 2026
- Funding instrument
- Grant
- Category
- Health
- Cost sharing required
- No
Who can apply
- •Special district governments
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •Public and State controlled institutions of higher education
- •Public housing authorities/Indian housing authorities
- •Independent school districts
- •Native American tribal governments (Federally recognized)
- •County governments
- •Private institutions of higher education
- •Small businesses
- •State governments
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •For profit organizations other than small businesses
- •City or township governments
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Synopsis
The purpose of this notice of funding opportunity (NOFO) is to elucidate the key components of the therapeutic effects of rapid-acting psychotropic interventional drugs (RAPIDs) by addressing the methodological challenges involved with these clinical trials. In addition, this NOFO seeks to advance understanding of how RAPIDs and adjunctive psychosocial interventions can be optimally delivered, monitored, and sustained over time to enhance effectiveness and generalizability. The NOFO will support studies designed to enhance the rigor of RAPID clinical trial design, which will ultimately increase the interpretability of the data and the generalizability of the results.
Contact
National Institutes of Health · DTRcommunications@nih.gov